Detailed information for compound 77731
Basic information
Technical information
- Name: Unnamed compound
- MW: 500.551 | Formula: C30H24N6O2
-
H donors: 2
H acceptors: 4
LogP: 3.41
Rotable bonds: 2
Rule of 5 violations (Lipinski): 2 - SMILES: N#Cc1ccc2cc1Oc1ccc3c(c1)c(ccc3)NC(=O)[C@H](NCc1n(C2)cnc1)Cc1cccnc1
- InChi: 1S/C30H24N6O2/c31-14-23-7-6-21-12-29(23)38-25-9-8-22-4-1-5-27(26(22)13-25)35-30(37)28(11-20-3-2-10-32-15-20)34-17-24-16-33-19-36(24)18-21/h1-10,12-13,15-16,19,28,34H,11,17-18H2,(H,35,37)/t28-/m1/s1
- InChiKey: IDVLFUHLBYSGQS-MUUNZHRXSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | farnesyltransferase, CAAX box, beta | References | |
| Homo sapiens | farnesyltransferase, CAAX box, alpha | Starlite/ChEMBL | References |
| Homo sapiens | protein geranylgeranyltransferase type I, beta subunit | Starlite/ChEMBL | References |
| Rattus norvegicus | Protein farnesyltransferase | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Trypanosoma brucei | protein farnesyltransferase beta subunit | protein geranylgeranyltransferase type I, beta subunit | 377 aa | 361 aa | 26.3 % |
Obtained from network model
Ranking Plot
Putative Targets List
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Cl (ADMET) | = 17.3 ml min-1 kg-1 | Clearance of the compound was determined by iv administration in dogs at a dose of 1 mg/kg | ChEMBL. | 11459639 |
| IC50 (functional) | = 1.8 nM | In vitro inhibitory activity to reduce the human farnesyltransferase catalyzed incorporation of [3H]-FPP into recombinant Ras-CVIM | ChEMBL. | 11459639 |
| IC50 (functional) | = 1.8 nM | In vitro inhibitory activity to reduce the human farnesyltransferase catalyzed incorporation of [3H]-FPP into recombinant Ras-CVIM | ChEMBL. | 11459639 |
| IC50 (binding) | = 1310 nM | In vitro ability of the compound to displace radiolabelled FTI from farnesyltransferase in cultured Ha-ras transformed RAT1 cells | ChEMBL. | 11459639 |
| IC50 (binding) | = 1310 nM | In vitro ability of the compound to displace radiolabelled FTI from farnesyltransferase in cultured Ha-ras transformed RAT1 cells | ChEMBL. | 11459639 |
| IC50 (functional) | = 0.147 uM | In vitro inhibitory activity to reduce the human geranylgeranyl transferase type I (GGPTase-1)-catalyzed incorporation of 3H GGPP (100 nM) into K-Ras-derived peptide | ChEMBL. | 11459639 |
| IC50 (functional) | = 0.147 uM | In vitro inhibitory activity to reduce the human geranylgeranyl transferase type I (GGPTase-1)-catalyzed incorporation of 3H GGPP (100 nM) into K-Ras-derived peptide | ChEMBL. | 11459639 |
| T1/2 (ADMET) | = 0.8 hr | Half life of the compound was determined | ChEMBL. | 11459639 |
| Vd (ADMET) | = 0.98 kg-1 | Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg | ChEMBL. | 11459639 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL52859
- PubChem: 22082993
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.